Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Mark Menzies MP resigns the Conservative whip. This as due to an ongoing internal investigation into his conduct. Jonathan Nunn, leader of West Northamptonshire Council, is accused of misconduct by five women. 19 April – In a speech on welfare, Prime Minister Rishi Sunak sets out plans to tackle what he describes as the UK's "sick note culture" by stripping GPs in England of their authority to sign people off work. Labour sets out plans to build more housing, with priority given to brownfield sites and poor quality greenbelt land dubbed "greybelt" land. It is announced that Scottish Green Party members will have a vote on the Bute House Agreement following the SNP ditching climate targets. Labour writes to Lancashire Police regarding allegations made against Mark Menzies. A review of information relating to the allegations is subsequently commenced. The Scottish Greens announce their intention to hold a vote on whether to stay in government with the Scottish National Party following the SNP's decision to scrap key climate targets. Biteback Publishing apologises over a false quote linked to an antisemitic conspiracy theory in Liz Truss's memoir, Ten Years to Save the West, and says it will be removed from future copies of the book. The Advisory Committee on Business Appointments rules that Boris Johnson broke government rules by being "evasive" about a meeting with Venezuelan president Nicolás Maduro. 20 April – BBC News reports that the SNP will form a minority government if the Scottish Greens vote to end their power-sharing agreement.
In diabetes, bolus is an extra amount of insulin given in a single dose to cover an expected rise in blood glucose (sugar), such as the rise that occurs after eating. Borderline Diabetes A term no longer used. See: Impaired glucose tolerance. Brittle diabetes A person with a blood glucose (sugar) level often swings quickly from high to low and from low to high. Also called labile and unstable diabetes. Bronze diabetes See: Hemochromatosis. Bunion A bump or bulge on the first joint of the big toe caused by the swelling of a sac of fluid under the skin.
Post-crash survivability is the chance that drivers and passengers survive a crash after it occurs. Technology such as Advanced Automatic Collision Notification can automatically place calls to emergency services and send information about a vehicle collision. Cars are much more dangerous to pedestrians than they are to drivers and passengers. Two-thirds of 1.3 million yearly auto related deaths are pedestrians. Since at least the early 1970s, attention has also been given to vehicle design regarding the safety of pedestrians in car-pedestrian collisions. Proposals in Europe would require cars sold there to have a minimum/maximum hood (bonnet) height. From 2006, the use of "bull bars", a fashion on 4x4s and SUVs, became illegal in the European Union, after having been banned on all new cars in 2002. Recent research has explored the use of multimodal sensor fusion to improve pedestrian detection in challenging conditions, including low-light environments and unusual pedestrian postures such as prone or fallen individuals.
Sources: en.wikipedia.org
Hazard research is published: an analysis of GBD study data shows pre-50 early-onset cancer cases rose by ~80% in 30 years (5 Sep), a study shows decoupling rates in high-income countries are inadequate for Paris Agreement commitments and suggests post-growth approaches such as demand reduction strategies and reorienting the economy (5 Sep), evidence of impacts of chronic and extreme heat exposure during pregnancy accumulates (7 Sep), a study shows early prevention of type 2 diabetes may save many years of life (11 Sep), a study estimates around 5 million adults died from cardiovascular disease due to lead exposure in 2019 (11 Sep), shortly after a review about biodiversity-related harmful effects on ecosystems by non-native ant invasions (29 Jul), the fifth-costliest invasive species, the red fire ant, is reported to have established itself in the warming Europe via colonies in Sicily (11 Sep), a product testing study shows cleaning products emit substantial amounts of hazardous VOCs, such as chloroform, with the lowest quantities in green fragrance-free products (12 Sep), the planetary boundaries framework assessment gets updated, incorporating freshwater change as a sixth Earth system dimension above its capacity limit (13 Sep), news outlets report on a study (31 Aug) that shows daily aspartame consumption leads to heritable cognitive deficits in mice – and more broadly that the exposome of men may also affect the mental health of the next generation (19 Sep), a study reports an increasing global exposure to air pollution from fires (20 Sep).
Ghana has a universal health care system, National Health Insurance Scheme (NHIS), which is strictly designated for Ghanaian nationals. Health care is variable throughout Ghana and in 2012, more than 12 million Ghanaian nationals were covered by the NHIS. Urban centres are served and contain most of the hospitals, clinics, and pharmacies. There are more than 200 hospitals, and Ghana is a destination for medical tourism. In 2010, there were 0.1 physicians per 1,000 people and as of 2011, 0.9 hospital beds per 1,000 people. In 2010, 5.2% of Ghana's GDP was spent on health. In 2020, the WHO announced Ghana became the second country in the WHO African Region to attain regulatory system "maturity level 3", the second-highest in the four-tiered WHO classification of National medicines regulatory systems. Life expectancy at birth in 2021 was 68.6 for a female and 63.7 for a male. In 2013, infant mortality was to 39 per 1,000 live births. Sources vary on life expectancy at birth; the World Health Organization (WHO) estimated 64 years for women and 62 years for men born in 2016. The fertility rate declined from 3.99 (2000) to 3.28 (2010) with 2.78 in urban region and 3.94 in rural region. The United Nations reports a fertility decline from 6.95 (1970) to 4.82 (2000) to 3.93 live births per woman in 2017. As of 2012, the HIV/AIDS prevalence was estimated at 1.40% among adults aged 15–49.
Recurrent or high-risk basal cell and cutaneous squamous cell carcinomas in anatomically or cosmetically sensitive areas. Specific cases of early-stage or surface-level melanoma (melanoma in situ or lentigo maligna), and thin invasive melanoma in similarly sensitive sites. Other rare skin cancers where all the margins need to be visualized.
Sources: en.wikipedia.org
Médecins Sans Frontières welcomed the decision, but criticized GSK for failing to include HIV patents in its patent pool and for not including middle-income countries in the initiative. In 2013, GSK licensed its HIV portfolio to the Medicines Patent Pool for use in children, and agreed to negotiate a license for dolutegravir, an integrase inhibitor then in clinical development. In 2014, this license was extended to include dolutegravir and adults with HIV. The licenses include countries in which 93 per cent of adults and 99 per cent of children with HIV live. Also in 2013 GSK joined AllTrials, a British campaign to ensure that all clinical trials are registered and the results reported. The company said it would make its past clinical-trial reports available and future ones within a year of the studies' end. GSK has largely had an access strategy, providing medicines at a subsidized price to lower and middle income markets including Africa under the former CEO Andrew Witty. In 2017, its new CEO, Emma Walmsley, shifted away from this with GSK exiting all Sub-Saharan African markets and there being no plans to provide its newer expensive oncology and genetics pipeline to this population.
=== Methyltransferases in the biosynthetic cluster === Bioinformatic analysis identified four methyltransferases within the cluster. Bioinformatics suggest that btmB, is an O-methyltransferase, while the other three, btmC, G and K, are radical S-adenosyl methionine (SAM) methyltransferases. The radical SAM methyltransferases are believed to β-methylate amino acid residues within the precursor peptide. btmC is believed to methylate phenylalanine, btmG is believed to methylate both valines, and btmK is believed to methylate proline based on gene deletion studies. The three putative radical SAM methyltransferases encoded within the pathway are interesting for both mechanistic and biosynthetic reasons. Radical SAM methyltransferases are likely to methylate substrates by an unusual mechanism. Biosynthetically, β-methylations of amino acids are highly unusual in natural products. Polytheonamide B, a peptide natural product produced by a marine symbiont, is the only other structurally characterized example of direct β-methylation of a peptide natural product. The proposed methyl transfer from a SAM-utilizing enzyme was supported by earlier feeding studies with labeled methionine; labeled methionine is used because methionine is converted into SAM within cells. Even further, this study used stereospecifically labeled methionine ([methyl-(2H-3H)]-(2S, methyl-R)-methionine) to show that methylation occurred with a net retention of stereochemistry at the methyl group. The author speculated that net retention indicated a radical mechanism with a B12 intermediate.
=== Medical === Hydrocodone/paracetamol is a fixed-dose combination consisting of the opioid hydrocodone and the non-opioid analgesic paracetamol. It is indicated for relief of moderate to severe pain of acute, chronic, or postoperative types. Hydrocodone/paracetamol comes in oral solution and tablet formulations; however strength of each component may vary. In October 2014, the Drug Enforcement Administration rescheduled hydrocodone combination drugs from schedule III, to schedule II due to its risk for misuse, abuse, and diversions.
== History == During the 1960s, a UK research team, headed by Professor John Vane, began to explore the role of prostaglandins in anaphylaxis and respiratory diseases. Working with a team from the Royal College of Surgeons, Vane discovered that aspirin and other oral anti-inflammatory drugs work by inhibiting the synthesis of prostaglandins. This critical finding opened the door to a broader understanding of the role of prostaglandins in the body. A team at The Wellcome Foundation led by Salvador Moncada had identified a lipid mediator they called "PG-X," which inhibits platelet aggregation. PG-X, later known as prostacyclin, is 30 times more potent than any other then-known anti-aggregatory agent. They did this while searching for an enzyme that generates a fellow unstable prostanoid, Thromboxane A2 In 1976, Vane and fellow researchers Salvador Moncada, Ryszard Gryglewski, and Stuart Bunting published the first paper on prostacyclin in Nature. The collaboration produced a synthesized molecule, which was named epoprostenol. But, as with native prostacyclin, the epoprostenol molecule is unstable in solution and prone to rapid degradation. This presented a challenge for both in vitro experiments and clinical applications. To overcome this challenge, the research team that discovered prostacyclin continued the research. The research team synthesized nearly 1,000 analogues.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.